| pubmed-article:19375046 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19375046 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19375046 | lifeskim:mentions | umls-concept:C0812413 | lld:lifeskim |
| pubmed-article:19375046 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:19375046 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:19375046 | lifeskim:mentions | umls-concept:C0210657 | lld:lifeskim |
| pubmed-article:19375046 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:19375046 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19375046 | pubmed:dateCreated | 2009-4-20 | lld:pubmed |
| pubmed-article:19375046 | pubmed:abstractText | Malignant pleural mesothelioma (MPM) is an aggressive disease with a poor prognosis. The optimal treatment of MPM was not clearly defined, until the publication of the multicentre, controlled and randomized phase III trial by Vogelzang et al. in 2003, which made the pemetrexed-cisplatin association the gold standard for the non-operable stages. Eleven patients with histologically proven pleural mesothelioma, not candidates for curative surgery, were assessed for eligibility and treated in our hospital. The response rate was similar to the reference study and the toxicity was acceptable. The median survival time was 12.7 months with an objective response rate of 45.5%. The median time to progression was 7.7 months. Neutropenia (all grades included) was the most common haematological toxicity (42.1%) although only one grade 3/4 was noted. Grade 3/4 anaemia and thrombocytopenia were not reported. Nausea and vomiting were the most commonly reported clinical toxicities with 81.8% reported (all grades included). One cutaneous allergic reaction was reported. The combination of pemetrexed and cisplatin chemotherapy provided the best objectives responses, but new therapeutic regimens are still warranted for these patients with a poor prognosis. The results were similar to those obtained in the Vogelzang et al.'s trial despite a selection bias because they correspond to 36.7% of the total recruitment in the unit. | lld:pubmed |
| pubmed-article:19375046 | pubmed:language | fre | lld:pubmed |
| pubmed-article:19375046 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19375046 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19375046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19375046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19375046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19375046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19375046 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19375046 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:19375046 | pubmed:issn | 0761-8417 | lld:pubmed |
| pubmed-article:19375046 | pubmed:author | pubmed-author:BurginMM | lld:pubmed |
| pubmed-article:19375046 | pubmed:author | pubmed-author:BeretsEE | lld:pubmed |
| pubmed-article:19375046 | pubmed:author | pubmed-author:MennecierBB | lld:pubmed |
| pubmed-article:19375046 | pubmed:author | pubmed-author:MolardAA | lld:pubmed |
| pubmed-article:19375046 | pubmed:author | pubmed-author:Gairard-DoryA... | lld:pubmed |
| pubmed-article:19375046 | pubmed:author | pubmed-author:QuoixA -EAE | lld:pubmed |
| pubmed-article:19375046 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19375046 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:19375046 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19375046 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19375046 | pubmed:pagination | 75-83 | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:meshHeading | pubmed-meshheading:19375046... | lld:pubmed |
| pubmed-article:19375046 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19375046 | pubmed:articleTitle | [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma]. | lld:pubmed |
| pubmed-article:19375046 | pubmed:affiliation | Service de pharmacie, stérilisation, pôle pharmacie, pharmacologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France. | lld:pubmed |
| pubmed-article:19375046 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19375046 | pubmed:publicationType | English Abstract | lld:pubmed |
